Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

49.66 -0.74 (-1.47%)
Streaming Delayed Price Updated: 10:20 AM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
36 37 Next >
News headline image
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
From Genentech
Via Business Wire
News headline image
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate... 
Via Benzinga
News headline image
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism ↗
 
Via Benzinga
News headline image
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin ↗
Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news. 
Via Investor's Business Daily
News headline image
Twitter Hackers Stole More Than 200M Emails, Delta Air Lines To Offer Free Wi-Fi, Bed Bath & Beyond's Bankruptcy Coming Sooner Than Expected: Top Stories Today ↗
Benzinga 
Via Benzinga
News headline image
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review ↗
 
Via Benzinga
News headline image
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
From Genentech
Via Business Wire
News headline image
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023? ↗
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall. 
Via Investor's Business Daily
News headline image
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock? ↗
Which of these companies is better able to replace declining COVID-19-related sales? 
Via The Motley Fool
News headline image
Big Health Care Stocks to Watch in the New Year
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now. 
Via MarketBeat
News headline image
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock ↗
Investors are closely watching two key spaces that could spark Lilly stock. 
Via Investor's Business Daily
News headline image
Roche's Follicular Lymphoma Therapy Scores FDA Approval ↗
 
Via Benzinga
News headline image
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
From Genentech
Via Business Wire
News headline image
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment ↗
 
Via Benzinga
News headline image
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
News headline image
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease ↗
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
News headline image
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
From Genentech
Via Business Wire
News headline image
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data ↗
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock. 
Via InvestorPlace
News headline image
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche ↗
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
News headline image
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ)... 
Via TheNewswire.com
Topics ETFs Economy Stocks
News headline image
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes ↗
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
Via Benzinga
News headline image
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates ↗
 
Via Benzinga
News headline image
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
From Spark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
From Genentech
Via Business Wire
News headline image
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12 ↗
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
News headline image
After 16 Years, Roche's Pharma Division Head Decides To Step Down ↗
 
Via Benzinga
News headline image
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
From Genentech
Via Business Wire
News headline image
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
From Genentech
Via Business Wire
News headline image
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.